Trial reportJournal of neurointerventional surgery2013
Importance of proper patient selection and endpoint selection in evaluation of new therapies in acute stroke: further analysis of the SENTIS trial.
Trial report in Journal of neurointerventional surgery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guidelines for evaluation and management of cerebral collateral circulation in ischaemic stroke 2017.Stroke and vascular neurology · 2018Guideline
- Poststroke epilepsy is associated with vascular cognitive disorder in young stroke patients: The ODYSSEY study.Epilepsia · 2026Article
- Development and external validation of the LEAN score to predict late seizures after intracerebral haemorrhage.European stroke journal · 2026Article
- Development and external validation of the LEAN score to predict late seizures after intracerebral haemorrhage.European stroke journal · 2025Article
- The impact of collateral therapeutics on stroke hemodynamics in normotensive and hypertensive rats: a step toward translation.Frontiers in neurology · 2024Article
- Therapeutic Induction of Collateral Flow.Translational stroke research · 2023Review
- Clinical Translation of Cell Therapies in Stroke (CT2S) Checklist-a pragmatic tool to accelerate development of cell therapy products.Stem cell research & therapy · 2021Article
- Transient Aortic Occlusion Augments Collateral Blood Flow and Reduces Mortality During Severe Ischemia due to Proximal Middle Cerebral Artery Occlusion.Translational stroke research · 2016Article
- Stroke Severity Is a Crucial Predictor of Outcome: An International Prospective Validation Study.Journal of the American Heart Association · 2016Article
- Collaterals: Implications in cerebral ischemic diseases and therapeutic interventions.Brain research · 2015Review
- Chinese consensus statement on the evaluation and intervention of collateral circulation for ischemic stroke.CNS neuroscience & therapeutics · 2014Article
- Augmenting collateral blood flow during ischemic stroke via transient aortic occlusion.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundThe magnitude of treatment effect in acute stroke depends on several factors, including time from symptom onset (TFSO) to treatment and severity of the initial insult.
objectiveTo report further evaluation of NeuroFlo therapy, focusing on the effect of time and stroke severity.
methodsSENTIS was a prospective randomized trial (N=515) comparing standard medical therapy with/without NeuroFlo therapy. For this analysis, we evaluated outcomes in groups of patients based on TFSO and stroke severity: patients randomized <6 h, 6-10 h, and >10 h with mild (NIHSS<8), moderate (8-14), and severe (>14) symptoms at randomization. 90-Day mRS (modified Rankin Scale) scores and stroke-related death rates were compared between treatment groups.
resultsFor patients randomized <6 h TFSO (n=128), the OR for mRS 0-2 was 3.11 (CI 1.30 to 7.46, p=0.011) for treated versus non-treated patients. In patients with disease of moderate severity (NIHSS 8-14, n=214), NeuroFlo-treated patients were more likely to have a good outcome (mRS 0-2; OR=1.84, CI 1.02 to 3.33, p=0.043). The stroke-related death rate was better in the treated group with TFSO >10 h and NIHSS >14 (n=42) (OR=7.10, CI 1.13 to 44.55, p=0.036).
conclusionsThe results of our analysis support the importance of careful selection of outcome measures and the impact that rapid treatment and initial stroke severity have on outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.